Search Filters

Search Results

Found 3 results

510(k) Data Aggregation

    K Number
    K030899
    Date Cleared
    2003-07-02

    (100 days)

    Product Code
    Regulation Number
    866.5270
    Reference & Predicate Devices
    Predicate For
    N/A
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The C-Reactive Protein assay is used for the quantitation of C-reactive protein in human serum or plasma. Measurement of C-reactive protein aids in evaluation of the amount of injury to body tissues.

    Device Description

    C-Reactive Protein is an in vitro diagnostic assay for the quantitative determination of C-reactive protein in human serum or plasma. The C-reactive protein is a latex enhanced immunoturbidimetric assay that involves an antigen-antibody reaction between the C-reactive protein in the sample and the anti-C-reactive protein, which has been adsorbed to latex particles. The resulting agglutination is detected as an absorbance change, with the magnitude of the change being proportional to the quantity of C-reactive protein in the sample. The actual concentration is then determined by interpolation from a calibration curve prepared from calibrators of known concentration.

    AI/ML Overview

    Here's an analysis of the provided text regarding the Abbott Laboratories C-Reactive Protein assay, focusing on acceptance criteria and the supporting study:

    The provided document is a 510(k) summary for the Abbott Laboratories C-Reactive Protein assay. This type of submission focuses on demonstrating substantial equivalence to a legally marketed predicate device rather than presenting a novel device's performance against pre-defined clinical acceptance criteria. Therefore, the "acceptance criteria" discussed here are primarily focused on equivalence to the predicate device, not absolute clinical performance thresholds.


    Acceptance Criteria and Reported Device Performance

    The study aims to demonstrate substantial equivalence to the predicate device, Dade Behring N High Sensitivity CRP (K991385). The key metrics for this demonstration are:

    Acceptance Criteria CategoryPredicate Device (Dade Behring N High Sensitivity CRP) PerformanceProposed Device (Abbott C-Reactive Protein) PerformanceMeets Criteria?
    Correlation CoefficientNot explicitly stated (implied as reference standard)0.996 (vs. predicate on BN™ 100)Yes
    SlopeNot explicitly stated (implied as reference standard)0.97 (vs. predicate on BN™ 100)Yes
    Y-interceptNot explicitly stated (implied as reference standard)0.07 mg/dL (vs. predicate on BN™ 100)Yes
    Precision (Within-run %CV)Not explicitly stated (implied by "similar clinical results" and "similar performance characteristics")Level 1: 1.2% - 2.0%
    Level 2: 1.0% - 2.3%
    Level 3: 1.0% - 1.3%Yes
    Precision (Between-run %CV)Not explicitly stated (implied by "similar clinical results" and "similar performance characteristics")Level 1: 1.2% - 2.0%
    Level 2: 1.0% - 2.3%
    Level 3: 1.0% - 1.3%Yes
    Precision (Between-day %CV)Not explicitly stated (implied by "similar clinical results" and "similar performance characteristics")Level 1: 1.2% - 2.0%
    Level 2: 1.0% - 2.3%
    Level 3: 1.0% - 1.3%Yes
    Assay RangeNot explicitly stated (implied to be comparable)0.22 to 30.00 mg/dLYes
    Limit of Quantitation (Sensitivity)Not explicitly stated (implied to be comparable)0.216 mg/dLYes
    Intended UseQuantitative determination of C-reactive protein in human serum/plasmaQuantitative determination of C-reactive protein in human serum/plasmaYes
    Methodology TypeIn vitro immunoassayIn vitro immunoassayYes

    Note: The acceptance criteria are implicitly defined by the demonstration of a strong correlation and similar precision and range to the legally marketed predicate device. The document states that the comparative performance "yielded acceptable correlation" and that the data "demonstrate that the performance... is substantially equivalent."


    Study Details

    1. Sample size used for the test set and the data provenance:

      • The document mentions "comparative performance studies" and "precision studies" using "three levels of control material." However, it does not specify the sample size for either the comparative performance (method comparison) study or the precision study.
      • Data Provenance: Not explicitly stated, but typically for such in-house studies, the data would be generated in a laboratory setting (e.g., in the US, where Abbott Laboratories is located). The data type is prospective as it involves running samples on both devices to compare performance.
    2. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

      • This question is not applicable in the context of this 510(k) submission for a quantitative diagnostic assay. The "ground truth" for a C-reactive protein assay is the actual concentration of CRP in the sample, measured by a reference method or through calibrated standards. The study compares the new device's measurements against a predicate device's measurements, where the predicate is assumed to provide accurate results.
    3. Adjudication method (e.g., 2+1, 3+1, none) for the test set:

      • This concept is not applicable to this type of quantitative diagnostic assay study. Adjudication methods like 2+1 or 3+1 are used in clinical studies involving interpretation of images or symptoms, where human experts reach a consensus. For a quantitative measurement device, the "truth" is typically derived from the measurement itself against a reference standard or predicate.
    4. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

      • No, an MRMC comparative effectiveness study was not done. This type of study is relevant for imaging devices or software that assist human interpretation. The C-Reactive Protein assay is a standalone in vitro diagnostic test for quantitative measurement, not an AI-assisted diagnostic tool requiring human interpretation.
    5. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done:

      • Yes, this was a standalone performance study. The device itself is an automated in vitro diagnostic test that quantitatively measures CRP. Its performance (correlation, precision, range, sensitivity) was assessed without human interpretation of the "results" beyond the initial sample loading and result readout from the analyzer.
    6. The type of ground truth used (expert consensus, pathology, outcomes data, etc.):

      • The "ground truth" in this context is the measurements obtained from the legally marketed predicate device (Dade Behring N High Sensitivity CRP on the Dade Behring BN™ 100). The study's primary goal is to show agreement with this predicate, implicitly assuming the predicate provides the "truth" for comparison purposes within the scope of substantial equivalence.
      • Additionally, calibrators of known concentration are used to establish the calibration curve for the proposed device, which forms part of its internal "truth" system.
    7. The sample size for the training set:

      • The document does not mention a training set in the context of machine learning or AI models. This is a traditional in vitro diagnostic assay, not an AI-driven device.
      • However, if "training set" refers to samples used for calibration, the document states the assay requires "calibration with calibrators" and that the concentration is determined by interpolation from a "calibration curve prepared from calibrators of known concentration." The number of calibrators used is not specified.
    8. How the ground truth for the training set was established:

      • As interpreted above, if "training set" refers to calibrators, their "ground truth" (i.e., their assigned concentration) would be established by manufacturing processes, chemical assays, and traceability to reference materials/standards. The document does not provide details on how these specific calibrators' concentrations were assigned, only that they are "of known concentration."
    Ask a Question

    Ask a specific question about this device

    K Number
    K962049
    Manufacturer
    Date Cleared
    1996-12-18

    (204 days)

    Product Code
    Regulation Number
    866.5270
    Reference & Predicate Devices
    N/A
    Predicate For
    N/A
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use
    Device Description
    AI/ML Overview
    Ask a Question

    Ask a specific question about this device

    K Number
    K962019
    Manufacturer
    Date Cleared
    1996-11-25

    (186 days)

    Product Code
    Regulation Number
    866.5270
    Reference & Predicate Devices
    N/A
    Predicate For
    N/A
    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use
    Device Description
    AI/ML Overview
    Ask a Question

    Ask a specific question about this device

    Page 1 of 1